Hyperprolactinemia and bone metabolism disorders due to antipsychotics in patients with schizophrenia;Şizofreni hastalarinda antipsikotik kullanimina baǧli hiperprolaktinemi ve kemik metabolizma bozukluklari

Anadolu Psikiyatri Dergisi

Volumn 10, Issue 4, 2009, Pages 336-342

  Karakuş, Gonca ^a   Tamam, Lut ^a   Zengin, Meliha ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Bone metabolism disorder; Hyperprolactinemia; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLORPROMAZINE; CLOZAPINE; COLECALCIFEROL; ERGOCALCIFEROL; FOLLITROPIN; GONADORELIN; HALOPERIDOL; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; OLANZAPINE; PARATHYROID HORMONE; RISPERIDONE; TUMOR NECROSIS FACTOR; VITAMIN D; ZIPRASIDONE;

ALCOHOL ABSTINENCE; BONE DENSITY; BONE METABOLISM; DIET SUPPLEMENTATION; DISEASE PREDISPOSITION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; LIFESTYLE MODIFICATION; METABOLIC BONE DISEASE; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; WEIGHT REDUCTION;

EID: 70849131951     PISSN: 13026631     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. van Kammen DP, Marder SR. Serotonin-dopamine antagonists (Atypical or second-generation antipsychotics). BJ Sadock, VA Sadock (Eds.), Kaplan&Sadock's Comprehensive Textbook of Psychiatry, eighth ed., Philadelphia, Lippincott Williams Wilkins, 2005, p.1329-1558.
2. Öztürk O, Uluşahin A. Ruh Saǧliǧi ve Bozukluklari. Ruhsal Bozukluklarda İlaç Saǧaltimi, 2. cilt, on birinci baski, Ankara, Nobel Tip Kitabevleri, 2008.
3. Halbreich U, Rojansky N, Palter S, Hreshchyshyn M, Kreeger J, Bakhai Y, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57:485-491.
4. Misra M, Papakostas GI ve Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004; 65:1607-1618.
5. Petty SJ, O'Brien TJ, Wark JD. Antiepileptic medication and bone health. Osteoporos Int 2007; 18:129-142.
6. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28;97-108. (Pubitemid 36332232)
7. Bilici M, Çakirbay H, Güler M,Tosun M, Ülgen M, Tan Ü. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 2002; 112:817-828. (Pubitemid 34890661)
8. Liu-Seifert H, Kinon BJ, Ahl J, Lamberson S. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin elevating antipsychotics. Ann NY Acad Sci 2004; 1032:297-298. (Pubitemid 40298499)
9. Becker D, Liver O, Mester R, Rapoport M, Weizman A, Weiss M. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003; 64:761-766. (Pubitemid 36897211)
10. Meaney AM, O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising antipsychotic medication. J Psychopharmacol 2003; 17:455-458. (Pubitemid 38076344)
11. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia. Drugs 2004; 64:2291-2314.
12. Hummer M, Malik P, Gasser RW, Hofer A, Kemmler G, Naveda RCM, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162:162-167.
13. Windgassen K, Wesselman U, Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and aetiology. Neuropsychobiology 1996; 33:142-146. (Pubitemid 26156190)
14. Ghadirian A, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170:463-467. (Pubitemid 12051650)
15. Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psycho-pharmacol 2007; 21:768-773. (Pubitemid 47437921)
16. Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M. Prolactin levels and ad-verse effects in patients treated with risperidone. J Clin Psychopharmacol 1999; 156:294-298.
17. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085-1096. (Pubitemid 30747129)
18. Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156:294-298. (Pubitemid 29077121)
19. Kinon B, Gilmore J, Liu H, Halbreich UM. Prevalance of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28(Suppl.2):55-68. (Pubitemid 36332229)
20. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry 2002; 63:408-413.
21. Bliesener N, Yokusoǧlu H, Quednow BB, Kling-müller D, Kühn KU. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia. Pharmacopsychiatry 2004; 37:189-191. (Pubitemid 38916429)
22. Grunder G, Wetzel H, Schloesser R, Anghelescu Ii Hillert A, Lange K, et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 1999; 45:89-97. (Pubitemid 29049209)
23. Turrone P, Kapur S, Seman M, Flint AJ. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002; 159:133-135.
24. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60:681-690. (Pubitemid 36818630)
25. Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, et al. An exploratory haloperidol-controlled dose findings study of ziprasidone in hospitalized patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 1998; 18:296-304. (Pubitemid 28353872)
26. Takahashi H, Higuchi H, Kamata M, Naitoh S, Yoshida K, Shimizu T, et al. Effectiveness of switching to quetiapine for neuroleptic-induced amenorrhea. J Neuropsychiatry Clin Neurosci 2003; 15:375-377. (Pubitemid 36999384)
27. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; 5:24-29.
28. Kishimoto T, Watanabe K, Takeuchi H, Kikuchi T, Nakajima S, Shimada N, et al. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 2005; 77:113-115. (Pubitemid 40957069)
29. Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002; 111:11-20. (Pubitemid 34879071)
30. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503-508. (Pubitemid 38725710)
31. Abraham G, Paing WW, Kaminski J, Joseph A, Kohegyi E, Josiassen RC. Effects of serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003; 160:1618-1620. (Pubitemid 41079547)
32. Baastrup PC, Christiansen C, Transbøl I. Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy. Neuropsychobiology 1980; 6:56-59. (Pubitemid 10136170)
33. Howes O. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2004; 66:77-78. (Pubitemid 38030348)
34. O'Keane V, Meaney AM. Antipsychotic drugs. A new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25:26-31.
35. Meaney AM, O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: Relationship to medication and endocrine variables. Schizophr Res 2007; 93:136-143. (Pubitemid 46817924)